Pathological characteristics and clinical course of bladder tumour developing after nephroureterectomy
Authors:
Open Access
- 25 March 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 105 (8) , 1102-1106
Abstract
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVES: To determine the pathological features and clinical course of intravesical recurrence after nephroureterectomy (NU) for upper urinary tract (UUT) cancer. PATIENTS AND METHODS: Among 325 patients undergoing NU with bladder cuff excision for UUT cancer, in this retrospective multi‐institutional study we evaluated 113 who developed bladder tumour after NU. Excluding patients with (i) perioperative systemic chemotherapy or radiotherapy for UUT cancer; (ii) a history of previous or synchronous bladder cancer at the time of NU; (iii) distant metastasis at the time of NU; (iv) a follow‐up of P < 0.001) and the carcinoma in situ (CIS) lesion with the first bladder cancer recurrence correlated with high grade (grade 3) UUT tumour ( P < 0.001). In all, 56 of the assessable 70 patients further developed intravesical recurrence at a median interval of 7 months after the first bladder cancer recurrence. There were no clinicopathological factors that predicted the second recurrence. Progression occurred in 14 patients, at a median interval of 25 months. A CIS lesion with the first bladder cancer recurrence was a risk factor for progression on multivariate analysis. CONCLUSIONS: A large proportion of the patients who developed bladder tumour after NU had further intravesical recurrence, which indicated its refractory nature. Especially when a CIS lesion is detected in the initial intravesical recurrence, a careful follow‐up is mandatory to detect bladder cancer progression.Keywords
This publication has 18 references indexed in Scilit:
- Pathologic Features of Bladder Tumors After Nephroureterectomy or Segmental Ureterectomy for Upper Urinary Tract Transitional Cell CarcinomaUrology, 2007
- Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour locationBJU International, 2006
- Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tractUrology, 2005
- Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathologyBJU International, 2005
- Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tractUrology, 2005
- The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tractCancer, 2003
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderAmerican Journal of Surgical Pathology, 1998
- Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinomaJournal of Surgical Oncology, 1994
- Transitional Cell Carcinoma of the Upper Urinary Tract: Prognostic Variables and Post‐operative RecurrencesBritish Journal of Urology, 1991
- Recurrence of Bladder Tumors following Surgery for Transitional Cell Carcinoma of the Upper Urinary TractEuropean Urology, 1991